Battle to get the best out of Market: Applied Therapeutics, Inc. (NASDAQ: APLT)
On Wednesday, Applied Therapeutics, Inc. (NASDAQ: APLT) changed -0.87% to recent value of $47.93. The stock transacted 178415 shares during most recent day however it has an average volume of 156.75K shares. It spotted trading -10.01% off 52-week high price. On the other end, the stock has been noted 502.89% away from the low price over the last 52-weeks.
Applied Therapeutics, Inc. (APLT) recently stated financial results for the third quarter ended September 30, 2019.
Financial Results
Cash and cash equivalents and short-term investments totaled $33.0M as of September 30, 2019, contrast with $18.8M at December 31, 2018. Subsequent to the close of the quarter, we closed a private placement of ordinary stock resulting in net proceeds of about $20M.
Research and development expenses for the three months ended September 30, 2019 were $7.5M, contrast to $2.7M for the three months ended September 30, 2018. The increase of about $4.8M was primarily related to the progressing of our clinical trials through development, including a raise in clinical and pre-clinical expenses of $4.0M and personnel expenses of $1.0MBecause of the hiring of research and development personnel, including the Chief Medical Officer in August 2018. These increases are offset by a decrease in drug manufacturing and formulation expenses of $0.1M and decrease in regulatory and other expenses of $0.1M.
General and administrative expenses were $3.3M for the three months ended September 30, 2019, contrast to $0.6M for the three months ended September 30, 2018. The increase of about $2.7M was primarily related to personnel expenses of $1.0MBecause of the increase in headcount, including the hiring of the Chief Financial Officer, professional fees of $0.9MBecause of increased legal and consulting fees, and other expenses of $0.8M, primarily Because of public relations efforts, travel expenses and recruiting efforts.
Net loss for the third quarter of 2019 was $10.7M, or $0.63 per basic and diluted ordinary share, contrast to a net loss of $4.3M, or $0.78 per basic and diluted ordinary share, for the third quarter of 2018.
The company has 17.09M of outstanding shares and 14.66M shares were floated in the market. According to the most recent quarter its current ratio was 5.7 that represents company’s ability to meet its current financial obligations. The price moved ahead of 39.22% from the mean of 20 days, 93.06% from mean of 50 days SMA and performed 229.94% from mean of 200 days price. Company’s performance for the week was 3.39%, 108.03% for month and YTD performance remained 75.70%.
